Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Steeg Website

Patricia S. Steeg, Ph.D.

Selected Publications

1)  McMullin RP, Wittner BS, Yang C, Denton-Schneider BR, Hicks D, Singavarapu R, Moulis S, Lee J, Akbari MR, Narod SA, Aldape KD, Steeg PS, Ramaswamy S, Sgroi DC.
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
Breast Cancer Res. 16: R25, 2014.
[Journal]
2)  Palmieri D, Duchnowska R, Woditschka S, Hua E, Qian Y, Biernat W, Sosilska-Mielcarek K, Gril B, Stark AM, Hewitt SM, Liewehr DJ, Steinberg SM, Jassem J, Steeg PS.
Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner.
Clin. Cancer Res. [Epub ahead of print], 2014.
[Journal]
3)  Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton P, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Janeway KA, Weigel BJ, Randall RL, Meltzer PS, Withrow SJ, Paoloni M, Kaplan R, Teicher BA, Seibel NL, Uren A, Patel S, Trent JM, Savage SA, Mirabello L, Reinke D, Barkauskas DA, Smith MA, Bernstein ML, Kirsch DG, Krailo MD.
Towards a Drug Development Path that Targets Metastatic Progression in Osteosarcoma.
Clin. Cancer Res. [Epub ahead of print], 2014.
[Journal]
4)  Peer CJ, Rao M, Spencer SD, Shahbazi S, Steeg PS, Schrump DS, Figg WD.
A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 927: 142-6, 2013.
[Journal]
5)  Marino N, Woditschka S, Reed LT, Nakayama J, Mayer M, Wetzel M, Steeg PS.
Breast cancer metastasis: issues for the personalization of its prevention and treatment.
Am. J. Pathol. 183: 1084-95, 2013.
[Journal]
6)  Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ, Steeg PS.
CNS metastases in breast cancer: old challenge, new frontiers.
Clin. Cancer Res. 19: 6404-18, 2013.
[Journal]
7)  Spano D, Marshall JC, Marino N, De Martino D, Romano A, Scoppettuolo MN, Bello AM, Di Dato V, Navas L, De Vita G, Medaglia C, Steeg PS, Zollo M.
Dipyridamole prevents triple-negative breast-cancer progression.
Clin. Exp. Metastasis. 30: 47-68, 2013.
[Journal]
8)  Saldana SM, Lee HH, Lowery FJ, Khotskaya YB, Xia W, Zhang C, Chang SS, Chou CK, Steeg PS, Yu D, Hung MC.
Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis.
PLoS ONE. 8: e73406, 2013.
[Journal]
9)  Wei JS, Johansson P, Chen L, Song YK, Tolman C, Li S, Hurd L, Patidar R, Wen X, Badgett TC, Cheuk AT, Marshall JC, Steeg PS, Vaqué Díez JP, Yu Y, Gutkind JS, Khan J.
Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma.
PLoS ONE. 8: e77731, 2013.
[Journal]
10)  Marino N, Marshall JC, Collins JW, Zhou M, Qian Y, Veenstra T, Steeg PS.
Nm23-h1 binds to gelsolin and inactivates its actin-severing capacity to promote tumor cell motility and metastasis.
Cancer Res. 73: 5949-62, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 5/16/2014.